Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?
Figure 1
Summary of timelines and procedures performed in the PET biodistribution study of the ASO LY2181308 in relation to the FHD study (a). (b) Is proposed flowchart of future streamlined timelines of PET biodistribution studies in relation to FHD oncology studies with NMEs.
